Suven Life Sciences Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘Suven Life Sciences Ltd. – Product Pipeline Review – 2016’, provides an overview of the Suven Life Sciences Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Suven Life Sciences Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Suven Life Sciences Ltd.

The report provides overview of Suven Life Sciences Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Suven Life Sciences Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Suven Life Sciences Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Suven Life Sciences Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Suven Life Sciences Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Suven Life Sciences Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Suven Life Sciences Ltd. Snapshot 5

Suven Life Sciences Ltd. Overview 5

Key Facts 5

Suven Life Sciences Ltd. - Research and Development Overview 6

Key Therapeutic Areas 6

Suven Life Sciences Ltd. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Suven Life Sciences Ltd. - Pipeline Products Glance 11

Suven Life Sciences Ltd. - Clinical Stage Pipeline Products 11

Phase II Products/Combination Treatment Modalities 11

Phase I Products/Combination Treatment Modalities 12

Suven Life Sciences Ltd. - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Suven Life Sciences Ltd. - Drug Profiles 14

Small Molecule for Psychiatric Disorders - Drug Profile 14

Product Description 14

Mechanism Of Action 14

R&D Progress 14

Small Molecule to Agonize Cannabinoid Receptor-2 for Pain - Drug Profile 15

Product Description 15

Mechanism Of Action 15

R&D Progress 15

Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for Pain - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

SUVN-501 - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

SUVN-502 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

SUVN-507 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

SUVN-512 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

SUVN-911 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

SUVND-4010 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

SUVNG-3031 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

SUVNI-1307014 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

SUVNI-1312004 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Suven Life Sciences Ltd. - Pipeline Analysis 31

Suven Life Sciences Ltd. - Pipeline Products by Target 31

Suven Life Sciences Ltd. - Pipeline Products by Route of Administration 32

Suven Life Sciences Ltd. - Pipeline Products by Molecule Type 33

Suven Life Sciences Ltd. - Pipeline Products by Mechanism of Action 34

Suven Life Sciences Ltd. - Dormant Projects 35

Suven Life Sciences Ltd. - Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

Suven Life Sciences Ltd., Key Facts 5

Suven Life Sciences Ltd. – Pipeline by Indication, 2016 8

Suven Life Sciences Ltd. – Pipeline by Stage of Development, 2016 9

Suven Life Sciences Ltd. – Monotherapy Products in Pipeline, 2016 10

Suven Life Sciences Ltd. – Phase II, 2016 11

Suven Life Sciences Ltd. – Phase I, 2016 12

Suven Life Sciences Ltd. – Preclinical, 2016 13

Suven Life Sciences Ltd. – Pipeline by Target, 2016 31

Suven Life Sciences Ltd. – Pipeline by Route of Administration, 2016 32

Suven Life Sciences Ltd. – Pipeline by Molecule Type, 2016 33

Suven Life Sciences Ltd. – Pipeline Products by Mechanism of Action, 2016 34

Suven Life Sciences Ltd. – Dormant Developmental Projects,2016 35

Suven Life Sciences Ltd., Other Locations 36

Suven Life Sciences Ltd., Subsidiaries 36

List of Figures

List of Figures

Suven Life Sciences Ltd. – Pipeline by Top 10 Indication, 2016 7

Suven Life Sciences Ltd. – Pipeline by Stage of Development, 2016 9

Suven Life Sciences Ltd. – Monotherapy Products in Pipeline, 2016 10

Suven Life Sciences Ltd. – Pipeline by Target, 2016 31

Suven Life Sciences Ltd. – Pipeline by Route of Administration, 2016 32

Suven Life Sciences Ltd. – Pipeline by Molecule Type, 2016 33

Suven Life Sciences Ltd. – Pipeline Products by Mechanism of Action, 2016 34

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports